Anbio Biotechnology (NNNN)
Nasdaq: NNNN · In Vitro & In Vivo Diagnostic Substances · Frankfurt Am Main, DE · filing with the SEC since 2023
Who runs Anbio Biotechnology
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Lau Michael
CEO. First filing Apr 2026, latest Apr 8, 2026, 0 filings in all.
Officers reporting now
3
of 7 people with a filing in the last fifteen months
Directors reporting now
4
7 people on the record since 2026
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Lau Michael | CEO | Apr 2026 | Apr 8, 2026 | none |
| Song Suki | CFO | Apr 2026 | Apr 8, 2026 | none |
| Tian Chris | CBO | Apr 2026 | Apr 8, 2026 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Hsu David H | director | Jun 2026 | Jun 12, 2026 | none |
| Zhang Michael W.C | director | Jun 2026 | Jun 12, 2026 | none |
| Hartzler Nancy | director | Apr 2026 | Apr 8, 2026 | none |
| Xu Cany | director | Apr 2026 | Apr 8, 2026 | none |
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.